Today, Fool.com health-care analysts Brenton Flynn and David Williamson take a look at Celgene's big winner -- Abraxane. The company purchased the drug a few years ago, and it has already been approved for breast cancer. Now Celgene is gunning for other major cancer approvals as well. Phase 3 data for Abraxane and melanoma has been favorable, and now the drug appears well positioned to take on Bristol-Myers Squibb's closest drug.
David thinks there are better ways to play Celgene than purchasing it directly. Watch the following video to learn more.
When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
Brenton Flynn, Dave Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.